1. Home
  2. NWFL vs PRTA Comparison

NWFL vs PRTA Comparison

Compare NWFL & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Norwood Financial Corp.

NWFL

Norwood Financial Corp.

N/A

Current Price

$37.31

Market Cap

366.2M

Sector

Finance

ML Signal

N/A

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

N/A

Current Price

$8.76

Market Cap

429.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NWFL
PRTA
Founded
1870
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
366.2M
429.2M
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
NWFL
PRTA
Price
$37.31
$8.76
Analyst Decision
Buy
Buy
Analyst Count
2
7
Target Price
★ $36.50
$21.40
AVG Volume (30 Days)
39.9K
★ 508.2K
Earning Date
10-27-2026
11-09-2026
Dividend Yield
★ 3.67%
N/A
EPS Growth
★ 15150.00
N/A
EPS
★ 1.21
0.26
Revenue
★ $7,999,000.00
$814,000.00
Revenue This Year
$32.93
$754.03
Revenue Next Year
$7.19
N/A
P/E Ratio
★ $28.83
$32.27
Revenue Growth
★ 8.11
N/A
52 Week Low
$25.50
$7.73
52 Week High
$35.48
$11.80

Technical Indicators

Market Signals
Indicator
NWFL
PRTA
Relative Strength Index (RSI) 78.19 54.41
Support Level $33.02 $8.08
Resistance Level N/A $9.18
Average True Range (ATR) 0.83 0.38
MACD 0.32 0.03
Stochastic Oscillator 97.94 58.18

Price Performance

Historical Comparison
NWFL
PRTA

About NWFL Norwood Financial Corp.

Norwood Financial Corp is a U.S.-based bank holding company. It offers various personal and business credit services, trust and investment products, and real estate settlement services to consumers, businesses, nonprofit organizations, and municipalities in each of the communities that the bank serves. The bank also manages automated teller machines at its branch location. It serves the Pennsylvanian counties of Wayne, Pike, Monroe, and Lackawanna, as well as Susquehanna County.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: